Trial Profile
A Multicentre Randomised Phase II Study to Assess the Safety and Resectability in Patients With Initially Unresectable Liver Metastases Secondary to Colorectal Cancer Receiving First-line Treatment Either With mFOLFOX-6 Plus Bevacizumab or FOLFOXIRI Plus Bevacizumab (OLIVIA)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Dec 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
- Indications Carcinoma; Colorectal cancer; Liver metastases
- Focus Therapeutic Use
- Acronyms OLIVIA
- Sponsors Roche
- 20 Aug 2020 Results (n=1697) of meta-analysis of 5 studies (CHARTA; NCT01321957, OLIVIA; NCT00778102, STEAM; NCT01765582, TRIBE; NCT00719797, and TRIBE2; NCT02339116) assessing survival, published in the Journal of Clinical Oncology.
- 31 May 2020 Results (n=1697) meta-analysis of meta-analysis of individual patient data from five studies (CHARTA (NCT01321957), OLIVIA (NCT00778102), STEAM (NCT01765582, only combined FOLFOXIRI/bev and FOLFOX/bev arms), TRIBE (NCT00719797) and TRIBE2 (NCT02339116)), presented at the 56th Annual Meeting of the American Society of Clinical Oncology.
- 21 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.